BRIEF—New Flagship firm takes in $109 million in series B round

A company launched by leading biotech incubator Flagship Pioneering has raised $109 million in a series B round led by its founder and a number of top-tier investors.

Alltrna is working on novel science around transfer RNA (tRNA), with the goal of creating a new class of medicines to regulate proteins.

The company is currently focused on targeting Stop Codon Disease, a collection of rare and more common disorders stemming from so-called nonsense mutations.

The firm’s platform is designed to optimize tRNA nucleotide sequences to create programmable medicines.

Chief executive Michelle Werner said: “Since launch, we’ve gained unparalleled insights into tRNA biology and shown that we can systematically design and deliver tRNAs with universal readthrough of premature termination codons and restore full-length functional protein production in vivo.”